Sanara MedTech, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US79957L1008
  • NASDAQ: SMTI
USD
35.15
-0.13 (-0.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
CareDx, Inc.
Sanara MedTech, Inc.
Tactile Systems Technology, Inc.
Anika Therapeutics, Inc.
Cerus Corp.
Utah Medical Products, Inc.
CVRx, Inc.
AngioDynamics, Inc.
AVITA Medical, Inc.
Orchestra Biomed Holdings, Inc.
Zynex, Inc.

Why is Sanara MedTech, Inc. ?

1
With a growth in Operating Profit of 246.67%, the company declared Outstanding results in Jun 26
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 5.7 MM
  • ROCE(HY) Highest at -1.31%
  • NET SALES(Q) Highest at USD 28.14 MM
2
High Institutional Holdings at 20.67%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Sanara MedTech, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sanara MedTech, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sanara MedTech, Inc.
6.19%
0.12
61.44%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
45.92%
EBIT Growth (5y)
22.95%
EBIT to Interest (avg)
-6.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.63
Sales to Capital Employed (avg)
1.35
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
25.19%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
26.18
EV to EBIT
45.55
EV to EBITDA
24.42
EV to Capital Employed
5.19
EV to Sales
1.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.40%
ROE (Latest)
-61.17%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 5.7 MM

ROCE(HY)

Highest at -1.31%

NET SALES(Q)

Highest at USD 28.14 MM

PRE-TAX PROFIT(Q)

At USD 0.7 MM has Grown at 135.16%

NET PROFIT(Q)

At USD 0.7 MM has Grown at 135.23%

RAW MATERIAL COST(Y)

Fallen by -1.06% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 8.94 times

-1What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 2.91 times

Here's what is working for Sanara MedTech, Inc.

Operating Cash Flow
Highest at USD 5.7 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 28.14 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 0.7 MM has Grown at 135.16%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 0.7 MM has Grown at 135.23%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Debtors Turnover Ratio
Highest at 8.94 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -1.06% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sanara MedTech, Inc.

Inventory Turnover Ratio
Lowest at 2.91 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Footer loading